Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer

Prostate

Volumn 74, Issue 15, 2014, Pages 1498-1505

  Guzel, Esra ^a,b   Karatas, Omer F ^a,c   Duz, Mehmet B ^a   Solak, Mustafa ^d   Ittmann, Michael ^e,f   Ozen, Mustafa ^a,b,e  

^a ISTANBUL UNIVERSITY   (Turkey)

^b BIRUNI UNIVERSITY   (Turkey)

^c ERZURUM TECHNICAL UNIVERSITY   (Turkey)

^d AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemoresistance; Prostate cancer; Recurrence; Stem cell markers

Indexed keywords

BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; POU5F1 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CHEMOSENSITIVITY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; SOXB1 TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84924285055     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22867     Document Type: Article

References (34)

1. Siegel R,Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-236.
2. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 2001;93(5):388-395.
3. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101:2371-2490.
4. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lövgren T, Lilja H. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154(3):1090-1095.
5. Group GDatVACUR. Histologic grading and staging of prostatic carcinoma. Tannenbaum M. Urologic Pathology Philadelphia: Lea & Febiger; 1977. pp. 171-187.
6. Dearnaley D. New developments in the treatment of localized prostate cancer. In: Prostate Cancer. 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Paris: 2006. p. 277.
7. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010;1:e105-e106.
8. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007;51(5):1175-1184.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951.
10. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104(3):973-978.
11. Komuro H, Saihara R, Shinya M, Takita J, Kaneko S, Kaneko M, Hayashi Y. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J Pediatr Surg 2007;42(12):2040-2045.
12. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006;103(30):11154-11159.
13. Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007;117(8):2044-2050.
14. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67(10):4807-4815.
15. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010;183(5):2045-2053.
16. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009;383(2):157-162.
17. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101(39):14228-14233.
18. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95(26): 15665-15670.
19. Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, Ozen M. miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS One 2014;9(6):e98675.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25(4):402-408.
21. Pavlidis P, Noble WS. Matrix2png: A utility for visualizing matrix data. Bioinformatics 2003;19(2):295-296.
22. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level
23. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, Correa R, Montorsi F, Graefen M, Huland H, Klein EA, Karakiewicz PI. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254-1263.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
25. Liu A, Yu X, Liu S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin J Cancer 2013;32(9):483-487.
26. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, Lv D, Liu CH, Tan X, Xiang R, Li N. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011;3(4):230-238.
27. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, Li D, Chen H, Zhao B, Zou H, Zheng X, Yu X. Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. Cell Prolif 2012;45(3):207-216.
28. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, TomW, Paner GP, Szmulewitz RZ, Vander Griend DJ. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One 2013;8(1):e53701.
29. Kastler S, Honold L, Luedeke M, Kuefer R, Möller P, Hoegel J, Vogel W, Maier C, Assum G. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 2010;70(6):666-674.
30. de Resende MF, Chinen LT, Vieira S, Jampietro J, da Fonseca FP, Vassallo J, Campos LC, Guimarães GC, Soares FA, Rocha RM. Prognostication of OCT4 isoform expression in prostate cancer. Tumour Biol 2013;34(5):2665-2673.
31. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kr ppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004;23(2):395-402.
32. Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, Spagnoli GC, Wyler S, Mengus C. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. Eur J Cancer 2013;49(4):955-963.
33. Gangavarapu KJ, Azabdaftari G, Morrison CD, Miller A, Foster BA, Huss WJ. Aldehyde dehydrogenase and ATP binding cassette transporter G2 (ABCG2) functional assays isolate different populations of prostate stem cells where ABCG2 function selects for cells with increased stem cell activity. Stem Cell Res Ther 2013;4(5):132-133.
34. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012;14(1):202-203.